Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00468832
Registration number
NCT00468832
Ethics application status
Date submitted
1/05/2007
Date registered
3/05/2007
Date last updated
21/04/2016
Titles & IDs
Public title
Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)
Query!
Scientific title
Longitudinal Study of the Relationship Between Impairment, Activity Limitation, Participation and Quality of Life in Persons With Confirmed Duchenne Muscular Dystrophy (DMD)
Query!
Secondary ID [1]
0
0
UCD0305
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Duchenne Muscular Dystrophy
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Ongoing Duchenne Muscular Dystrophy (DMD) Cohort - 340 patients currently enrolled participants with DMD.
New Young Duchenne Muscular Dystrophy (DMD) Cohort - Additional 100 confirmed DMD participants aged 4-7 years old to be recruited.
Typically Developing Control Cohort - Up to 370 typically developing male children and adults aged 6-30 years old to be recruited.
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Strength and function
Query!
Assessment method [1]
0
0
These assessments include:
Quantitative muscle testing
Manual muscle testing
Pulmonary function testing
Functional evaluations (nine hole peg, six minute walk, North Star ambulatory assessment, Brooke and Vignos scales, Egen Klassification (EK) scale, and range of motion).
Query!
Timepoint [1]
0
0
Collected at yearly visits
Query!
Primary outcome [2]
0
0
Quality of life
Query!
Assessment method [2]
0
0
These questionnaires include:
Pediatric Quality of Life Inventory (PedsQL)
Pediatric Orthopaedic Functional Health Questionnaire of the Pediatric Orthopaedic Society of North America (POSNA)
World Health Organization Quality of Life Assessment - Brief (WHO QOL Brief)
Pediatrics and Adult Neuromuscular module Quality of Life (NeuroQOL)
Review of Systems
Query!
Timepoint [2]
0
0
Collected at yearly visits
Query!
Primary outcome [3]
0
0
Medical history assessment
Query!
Assessment method [3]
0
0
Outcomes on ambulation status, medication history, hospitalizations, surgeries, nutrition, fractures, and cardiac tests.
Query!
Timepoint [3]
0
0
Collected at yearly visits
Query!
Secondary outcome [1]
0
0
Biomarkers and genetic modifiers
Query!
Assessment method [1]
0
0
Genotyping and Serum Biomarkers include blood/saliva collection for:
Blood collection for Genome Wide Association Study (GWAS) analysis (one time sample, any visit)
Blood or saliva collection for SNP sample (one time sample, any visit)
Blood collection for biomarker analysis (collected at each visit)
Query!
Timepoint [1]
0
0
Collected either once at any visit or each visit
Query!
Eligibility
Key inclusion criteria
DMD Subject Inclusion Criteria
- Affected subjects must be male and between the ages of 2 and 30
- Affected subjects between the ages of 2 and 4 must have a diagnosis of DMD confirmed
by at least one the following OR have an older male sibling that meet at least one of
the following criteria:
- Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin
deficiency, and clinical picture consistent with typical Duchenne dystrophy OR
- Gene deletion test positive (missing one or more exons) in the central rod domain
exons 25-60) of dystrophin, where reading frame can be predicted as
'out-of-frame',and clinical picture consistent with typical Duchenne dystrophy.
- Complete dystrophin gene sequencing showing an alteration (point mutation,
duplication, other) that is expected to preclude production of the dystrophin
protein(i.e. nonsense mutation, deletion/duplication leading to a downstream stop
codon),with a typical clinical picture of DMD.
- Affected subjects between the ages of 5 and 30 must either fulfill the above criteria
OR show evidence of a dystrophinopathy and clinical picture consistent with Duchenne
Muscular Dystrophy
- Participants who have documented clinical symptoms referable to a
dystrophinopathy and direct support of the diagnosis by either (1) a positive DNA
analysis for dystrophin mutation, (2) a muscle biopsy demonstrating abnormal
dystrophin, or (3) an elevated CK (>5X normal), and X-linked pedigree and an
affected family member who meets either criterion (1) or (2) as described above.
NOTE: Determination of the appropriate clinical symptoms consistent with DMD will generally
be the responsibility of the clinician. At a minimum this will include progressive loss of
function, with additional consideration for other clinical features such as a
characteristic gait, a positive Gower sign and calf pseudohypertrophy. When immunostaining
of muscle biopsy is used to determining case definition, the clinical reviewer (site PI)
should confirm that appropriate testing has ruled out a secondary deficiency of dystrophin.
Affected subjects that do not exhibit the above symptoms consistent with DMD should be
excluded.
o Muscle weakness prevalent by 5 years of age
- Non-affected adult subjects must be Parent(s) or legal guardian(s) of an eligible
affected subject.
DMD Serum Biomarker Inclusion Criteria
- Participants must meet eligibility criteria for the DMD phenotyping portion of this
study
- For the GC-treatment response cohort, participants must initiate GC treatment within
the first year of study participation (i.e. between their first study visit and their
one year follow-up visit)
DMD Subject
Query!
Minimum age
2
Years
Query!
Query!
Maximum age
30
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Exclusion Criteria
For those subjects that confirm DMD diagnosis through a clinical picture consistent with
DMD
- Steroid-naïve subjects ambulating past the 13th birthday
- Steroid users ambulating past the 16th birthday
- Subjects/families who are unwilling or unable to comply with the protocol study
procedures or visits
Controls Subject Inclusion Criteria
- Male sex
- Age 6-30 years
- Able to comply with functional testing instructions
Control Serum Biomarker Inclusion criteria
- Participants must be male
- Participants must be free of DMD, other neuromuscular disease, or other significant
concomitant illness
- Participant must be free of glucocorticoid therapy
Control Subject Exclusion Criteria
- Musculoskeletal disease
- Musculoskeletal injury within 6 months of enrollment
- Other concomitant illness that precludes functional testing in the judgment of the
investigator or clinical evaluator
- Completion of enrollment for age cohort
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Unknown status
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2019
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
551
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
The Children's Hospital at Westmead - Sydney
Query!
Recruitment hospital [2]
0
0
Royal Children's Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2145 - Sydney
Query!
Recruitment postcode(s) [2]
0
0
3052 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
District of Columbia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Minnesota
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Tennessee
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Virginia
Query!
Country [11]
0
0
Argentina
Query!
State/province [11]
0
0
Buenos Aires
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Alberta
Query!
Country [13]
0
0
Canada
Query!
State/province [13]
0
0
Ontario
Query!
Country [14]
0
0
India
Query!
State/province [14]
0
0
Chennai
Query!
Country [15]
0
0
Israel
Query!
State/province [15]
0
0
Petach Tikvah
Query!
Country [16]
0
0
Italy
Query!
State/province [16]
0
0
Milan
Query!
Country [17]
0
0
Sweden
Query!
State/province [17]
0
0
Gothenburg
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Cooperative International Neuromuscular Research Group
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Government body
Query!
Name [1]
0
0
U.S. Department of Education
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Government body
Query!
Name [2]
0
0
National Institutes of Health (NIH)
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Government body
Query!
Name [3]
0
0
United States Department of Defense
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
Parent Project Muscular Dystrophy
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to establish the largest long-term assessment of people with
Duchenne muscular dystrophy (DMD). In this study, the investigators associated with the
Cooperative International Neuromuscular Research Group CINRG) will take a detailed look (for
a minimum of eight years) at DMD participant's physical abilities, the medical problems they
experience, and how they use health care services. Physical abilities will be compared to a
group of healthy controls.
The second purpose of this study is to find out whether small, normal differences in the
genetic makeup of people with DMD (called "single nucleotide polymorphisms" or "SNPs") affect
how their disease progresses and relates to muscle strength/size and steroid response.
The third purpose of this study is to study genetic variations associated with DMD.
The final purpose of this study is to determine whether certain biomarkers are present in
people with DMD and not in healthy controls.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00468832
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Craig McDonald, MD
Query!
Address
0
0
University of California, Davis
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00468832
Download to PDF